@article {1273,
	title = {Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs},
	journal = {Transfusion},
	volume = {41},
	year = {2001},
	note = {Platzbecker, U Prange-Krex, G Bornhauser, M Koch, R Soucek, S Aikele, P Haack, A Haag, C Schuler, U Berndt, A Rutt, C Ehninger, G Holig, K United States Transfusion Transfusion. 2001 Feb;41(2):184-9.},
	month = {Feb},
	pages = {184 - 9},
	edition = {36960},
	abstract = {BACKGROUND: Recombinant human G-CSF is widely used to mobilize PBPCs in healthy donors for allogeneic transplantation. There have been concerns about donor safety because of splenic ruptures during G-CSF application. To address this problem, changes in splenic size in 91 healthy donors during G-CSF mobilization of allogeneic PBPCs were investigated. STUDY DESIGN AND METHODS: For mobilization, G-CSF in a dosage of 7.5 microg per kg per day was administered for 5 days and PBPC collection started Day 5. Splenic size was determined by ultrasound before G-CSF application was started and on the day of the first apheresis. RESULTS: The mean increase in splenic length was 11 mm (range, 0-28 mm; p<0.0001), whereas a mean increase of 5 mm in width (range, 0-14 mm; p<0.0001) was measured. No major side effects could be observed. There was no significant correlation between the increase in splenic size and the hematologic values, or the age and body-mass index. In a multivariant analysis, no independent risk factor for the development of a spleen enlargement over 19 mm in length and 9 mm in thickness was found in 20 percent of investigated donors. CONCLUSION: In this prospective trial, a significant spleen enlargement was observed in healthy donors during G-CSF mobilization of allogeneic PBPCs. Further investigations are needed to define the degree of spleen enlargement with higher G-CSF dosages to improve donor safety.},
	keywords = {*Blood Donors, *Hematopoietic Stem Cell Mobilization, Granulocyte Colony-Stimulating Factor / *pharmacology, Hematopoietic Stem Cells / drug effects / *metabolism, Humans, Prospective Studies, Spleen / drug effects, Splenomegaly / *blood},
	issn = {0041-1132 (Print) 0041-1132 (Linking)},
	author = {Platzbecker,U. and Prange-Krex,G. and Bornhauser,M. and Koch,R. and Soucek,S. and Aikele,P. and Haack,A. and Haag,C. and Schuler,U. and Berndt,A. and Rutt,C. and Ehninger,G. and Holig,K.}
}
